Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers

Modern Pathology

Volumn 27, Issue 5, 2014, Pages 711-720

  Yoshida, Akihiko ^a   Tsuta, Koji ^a   Wakai, Susumu ^a   Arai, Yasuhito ^b   Asamura, Hisao ^a   Shibata, Tatsuhiro ^b   Furuta, Koh ^a   Kohno, Takashi ^b   Kushima, Ryoji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

adenocarcinoma; immunohistochemistry; lung; ROS1

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN; PROTEIN EZR; PROTEIN ROS1; UNCLASSIFIED DRUG; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CELL MEMBRANE; CYTOPLASM; GENE EXPRESSION; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; LUNG PARENCHYMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGNET RING CARCINOMA; TISSUE MICROARRAY; TUMOR INVASION; ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION STUDY;

ADENOCARCINOMA; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899989532     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.192     Document Type: Article

References (28)

1. Sawabata N, Asamura H, Goya T, et al. Japanese LungCancer Registry Study: first prospective enrollment ofa large number of surgical and nonsurgical cases in2002. J Thorac Oncol 2010;5:1369-1375.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplasticlymphoma kinase inhibition in non-small-cell lungcancer. N Engl J Med 2010;363:1693-1703.
3. Lynch TJ, Bell DW, Sordella R, et al. Activatingmutations in the epidermal growth factor receptorunderlying responsiveness of non-small-cell lungcancer to gefitinib. N Engl J Med 2004;350:2129-2139.
4. Rikova K, Guo A, Zeng Q, et al. Global survey ofphosphotyrosine signaling identifies oncogenic kinasesin lung cancer. Cell 2007;131:1190-1203.
5. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangementsdefine a unique molecular class of lung cancers.J Clin Oncol 2012;30:863-870.
6. Davies KD, Le AT, Theodoro MF, et al. Identifying andtargeting ROS1 gene fusions in non-small cell lungcancer. Clin Cancer Res 2012;18:4570-4579.
7. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 andALK fusions in lung cancer. Nat Med 2012;18:378-381.
8. Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearrangedlung cancer: a clinicopathologic and molecular studyof 15 surgical cases. Am J Surg Pathol 2013;37:554-562.
9. Rimkunas VM, Crosby K, Kelly M, et al. Analysis ofreceptor tyrosine kinase ROS1 positive tumors in nonsmallcell lung cancer: identification of a FIG-ROS1fusion. Clin Cancer Res 2012;18:4449-4457.
10. Suehara Y, Arcila M, Wang L, et al. Identification ofKIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomasthrough a comprehensive mRNA-basedscreen for tyrosine kinase fusions. Clin Cancer Res2012;18:6599-6608.
11. Govindan R, Ding L, Griffith M, et al. Genomiclandscape of non-small cell lung cancer in smokersand never-smokers. Cell 2012;150:1121-1134.
12. Seo JS, Ju YS, Lee WC, et al. The transcriptionallandscape and mutational profile of lung adenocarcinoma.Genome Res 2012;22:2109-2119.
13. Arai Y, Totoki Y, Takahashi H, et al. Mouse model forROS1-rearranged lung cancer. PLoS One 2013;8:e56010.
14. Shaw A, Camidge D, Engelman J, et al. Clinical activityof crizotinib in advanced non-small cell lung cancer(NSCLC) harboring ROS1 gene rearrangement. J ClinOncol 2012;30:Suppl; abstr 7508.
15. Li C, Fang R, Sun Y, et al. Spectrum of oncogenicdriver mutations in lung adenocarcinomas from EastAsian never smokers. PLoS One 2011;6:e28204.
16. Acquaviva J, Wong R, Charest A. The multifacetedroles of the receptor tyrosine kinase ROS in developmentand cancer. Biochim Biophys Acta 2009;1795:37-52.
17. Lee HJ, Seol HS, Kim JY, et al. ROS1 receptor tyrosinekinase, a druggable target, is frequently overexpressedin non-small cell lung carcinomas via genetic andepigenetic mechanisms. Ann Surg Oncol 2013;20:200-208.
18. Fukui T, Ohe Y, Tsuta K, et al. Prospective study of theaccuracy of EGFR mutational analysis by high-resolutionmelting analysis in small samples obtained frompatients with non-small cell lung cancer. Clin CancerRes 2008;14:4751-4757.
19. Charest A, Lane K, McMahon K, et al. Fusion of FIG tothe receptor tyrosine kinase ROS in a glioblastomawith an interstitial del(6)(q21q21). Genes ChromosomesCancer 2003;37:58-71.
20. Travis WD, Brambilla E, Noguchi M, et al. InternationalAssociation for the Study of Lung Cancer/American Thoracic Society/European RespiratorySociety International multidisciplinary classificationof lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
21. Camidge DR, Kono SA, Flacco A, et al. Optimizing thedetection of lung cancer patients harboring anaplasticlymphoma kinase (ALK) gene rearrangements potentiallysuitable for ALK inhibitor treatment. Clin CancerRes 2010;16:5581-5590.
22. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneousdistribution of EGFR mutations is extremely rarein lung adenocarcinoma. J Clin Oncol 2011;29:2972-2977.
23. Stumptner-Cuvelette P, Benaroch P. Multiple roles ofthe invariant chain in MHC class II function. BiochimBiophys Acta 2002;1542:1-13.
24. Bruce B, Khanna G, Ren L, et al. Expression of thecytoskeleton linker protein ezrin in human cancers.Clin Exp Metastasis 2007;24:69-78.
25. Murakami Y, Mitsudomi T, Yatabe Y. A screeningmethod for the ALK fusion gene in NSCLC. FrontOncol 2012;2:24.
26. Sasaki T, Koivunen J, Ogino A, et al. A novel ALKsecondary mutation and EGFR signaling cause resistanceto ALK kinase inhibitors. Cancer Res 2011;71:6051-6060.
27. Lee J, Lee SE, Kang SY, et al. Identification of ROS1rearrangement in gastric adenocarcinoma. Cancer2013;119:1627-1635.
28. Gu TL, Deng X, Huang F, et al. Survey of tyrosinekinase signaling reveals ROS kinase fusions in humancholangiocarcinoma. PLoS One 2011;6:e15640.